MTVA

MetaViaD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

Current thesis

The post-earnings company materials kept the constructive operating story intact: DA-1726 Part 3 is underway, management is leaning into higher-dose titration to improve tolerability, and prior 48 mg data are being used to argue best-in-class potential in obesity and cardiometabolic disease [#8-K-2026-05-14] [#10-Q-2026-05-14].

Posture

Defensive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite.

What can break

Cash runway is guided only into Q4 2026, keeping dilution or other financing highly likely if development timelines slip [#10-Q-2026-05-14] [#10-K-2026-03-26].

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $1.00 · Bull $2.50 · Bear $0.40Analysis 2026-05-15; returns require an exact persisted reference.

Data freshness

Prices

Unavailable: Price unavailable

Fundamentals

As of 2026-08-17 • Vendor: Data Vendor v1

Scores

As of 2026-09-11 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-09-11

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $19.33

Why

Momentum69 · Δ7d -

Value58 · Δ7d 0.0

Sentiment29 · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

• Sentiment remains the lead driver in the composite.

Contradictions & invalidation

• Cash runway is guided only into Q4 2026, keeping dilution or other financing highly likely if development timelines slip [#10-Q-2026-05-14] [#10-K-2026-03-26].
• DA-1726 remains early-stage; Part 3 is specifically trying to improve tolerability while escalating dose, so clinical execution or adverse-event setbacks would matter disproportionately [#10-Q-2026-05-14].
• The Q1 update did not solve the core financing problem.

Catalyst clock

2026-05-31

Post-earnings digestion of May 14 update may keep shares event-driven

Lead driver: Sentiment · See AI snapshot

Momentum

9% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

28% active weight

Current posture

7d trendFlat

Δ7d

0.0

Δ21d

+0.1

Sentiment

62% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade D. Momentum 69.4 / Value 58.4 / Sentiment 29.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method

B+

Bull case

25%

Probability

Target price

$2.50

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.00

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.40

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

Fundamentals (TTM)

As of 2026-08-17

Market Cap

$9.75M

Beta

0.28

Shares Out

6.59M

P/E (TTM) · Derived

-0.2

P/S (TTM)

P/FCF (TTM) · Derived

-0.23

Rev YoY

EPS YoY

-68.8%

Gross Margin

Op Margin

Net Debt

-$10.07M

Current Ratio

2.06

As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data